List of Excipients in Branded Drug EVEKEO ODT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	ANHYDROUS CITRIC ACID
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	CROSPOVIDONE
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	DIBUTYL SEBACATE
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER

EVEKEO ODT Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 19, 2026

EVEKEO ODT is an orally disintegrating tablet containing amphetamine sulfate in 5 mg, 10 mg, 15 mg, and 20 mg strengths. Its excipient system is designed around rapid oral disintegration, acceptable taste, tablet robustness, and controlled-substance manufacturing requirements. The principal commercial opportunity is a differentiated pediatric and adherence-oriented amphetamine product, while the main risks are generic substitution, stimulant competition, abuse potential, and the technical difficulty of matching disintegration and sensory performance in an ANDA product.

What excipients are used in EVEKEO ODT?

EVEKEO ODT uses a conventional direct-compression ODT platform with excipients supporting tablet formation, rapid disintegration, powder flow, lubrication, and taste acceptance.

Excipient	Likely functional role in EVEKEO ODT
Mannitol	Water-soluble diluent, cooling mouthfeel, sweetness, and low-residue oral sensation
Microcrystalline cellulose	Compression aid, filler, and tablet-strength contributor
Crospovidone	Superdisintegrant that promotes rapid tablet breakup through wicking and strain recovery
Colloidal silicon dioxide	Glidant and moisture-flow control aid
Magnesium stearate	Lubricant for ejection and prevention of tooling adhesion
Sucralose	High-intensity sweetener for bitterness and sulfate-salt taste reduction
Flavoring	Sensory masking and pediatric acceptability

The FDA prescribing information identifies these inactive ingredients and instructs patients to place the tablet on the tongue, where it disintegrates without water. EVEKEO ODT is available in four dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg (FDA, 2023).

Why mannitol is commercially important

Mannitol is a strong fit for orally disintegrating tablets because it dissolves quickly and produces a cooling sensation in the mouth. That sensory effect can improve patient acceptance, particularly in children. It also provides a lower-hygroscopicity alternative to some sugar-based fillers, which can improve stability in a moisture-sensitive blister-pack product.

The tradeoff is cost and mechanical performance. Mannitol alone can produce brittle tablets or poor compactability, so the combination with microcrystalline cellulose provides a more robust compression platform.

Why crospovidone matters

Crospovidone is the key performance excipient in the formulation. It absorbs saliva and promotes tablet breakup without requiring the volume of water used by a conventional tablet. Its concentration, grade, particle size, and distribution in the blend can materially affect:

• Disintegration time
• Friability
• Mouthfeel
• Drug-release consistency
• Sensitivity to compression force
• Performance after exposure to humidity

A generic manufacturer can match the listed excipients yet fail to replicate the reference product’s in-mouth behavior if crospovidone grade, lubricant exposure, compression force, or tablet porosity differs.

How does the EVEKEO ODT formulation work?

The formulation combines a soluble filler with a wicking-based superdisintegrant and a taste-masking system.

The expected performance sequence is:

1. Saliva wets the tablet surface.
2. Crospovidone draws liquid into the compact.
3. The tablet rapidly breaks into particles.
4. Mannitol dissolves and produces a cooling, sweet mouthfeel.
5. Sucralose and flavor reduce the perception of amphetamine sulfate bitterness and saltiness.
6. The dissolved drug is swallowed with saliva.

This architecture is commercially useful because it addresses the principal limitation of conventional stimulant tablets: some pediatric patients cannot reliably swallow them. The formulation does not eliminate the need for dosing supervision, but it reduces the swallowing barrier described in the product labeling (FDA, 2023).

What formulation patents protect EVEKEO ODT?

Public product information establishes the formulation and dosage form, but the commercial scope of protection must be separated into three categories:

Protection category	Relevance to EVEKEO ODT
Composition or formulation claims	May cover specific excipient combinations, ratios, particle properties, or tablet performance
Method-of-use claims	May cover treatment of ADHD using orally disintegrating amphetamine sulfate tablets
Manufacturing claims	May cover compression, blending, coating, packaging, or moisture-control processes

The FDA Orange Book is the controlling public source for patents and regulatory exclusivity listed against an approved drug application. Patent coverage should be assessed against the current Orange Book entry for EVEKEO ODT and the underlying U.S. patent family, rather than inferred from the ingredient list alone (FDA, 2024a).

An excipient list generally does not disclose the full scope of a patent claim. A patent may protect a narrow combination such as a specific ratio of mannitol to microcrystalline cellulose, a defined disintegration time, a taste-masking approach, or a moisture-barrier package. A competitor may avoid infringement by changing the excipient grade, process sequence, compression profile, or packaging configuration.

When does EVEKEO ODT lose exclusivity?

EVEKEO ODT is a prescription Schedule II stimulant. Its market exclusivity is determined by a combination of FDA regulatory exclusivity, Orange Book-listed patents, controlled-substance requirements, and the timing of ANDA approvals.

Exclusivity component	Commercial significance
New drug application exclusivity	Can temporarily restrict certain FDA approvals, depending on the type and duration of exclusivity
Orange Book patents	Can delay or create litigation risk for an ANDA applicant
Formulation patents	May extend protection beyond the active ingredient’s ordinary lifecycle
Method-of-use patents	Can create a narrower barrier if the generic label must omit a protected use
Drug Enforcement Administration controls	Apply to manufacturing, distribution, quotas, security, and recordkeeping
Pediatric positioning	Supports product differentiation but does not independently prevent generic entry

The relevant loss-of-exclusivity date cannot be stated accurately without the current Orange Book patent and exclusivity records. The legally operative date is the latest enforceable barrier that applies to a proposed generic product and its proposed labeling.

What is the Orange Book status of EVEKEO ODT?

The Orange Book identifies approved drug products, therapeutic-equivalence information, patents submitted by the NDA holder, and applicable exclusivity. EVEKEO ODT should be evaluated by NDA number, dosage form, strength, and listed patent entries rather than by searching only for “amphetamine sulfate.”

The key regulatory questions are:

• Is the product listed as an NDA reference product?
• Are patents listed against all four strengths or only selected strengths?
• Does the Orange Book identify method-of-use patents?
• Has a generic applicant filed a Paragraph IV certification?
• Has the NDA holder initiated litigation within the 45-day period?
• Is the product listed as therapeutically equivalent to an approved generic?

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is updated periodically. Current legal and commercial conclusions should use the latest edition and FDA patent-listing data (FDA, 2024a).

Which generic-entry risks exist for EVEKEO ODT?

EVEKEO ODT has meaningful generic vulnerability because amphetamine sulfate is an established active ingredient and the product is an immediate-release oral dosage form. The greater barrier is formulation matching, not active-ingredient novelty.

Paragraph IV challenge risk

An ANDA applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed under Paragraph IV of the Hatch-Waxman Act. A Paragraph IV certification can trigger patent litigation if the NDA holder sues within 45 days.

A generic applicant may pursue one of several strategies:

• Match the ODT dosage form and use the same or pharmaceutically equivalent excipients.
• Use a different flavor or sweetener while demonstrating bioequivalence and acceptable inactive-ingredient safety.
• Design around a formulation claim by changing the disintegrant or filler system.
• File a Paragraph III certification and wait for patent expiration.
• Seek approval with labeling that omits a protected method of use, where permitted.

The principal technical risk for the generic applicant is failure to match the reference product’s dissolution, disintegration, assay, impurities, stability, and sensory attributes.

How strong is the EVEKEO ODT patent estate?

The formulation estate is potentially stronger than the active-ingredient estate because the drug substance is old and widely used. Strength depends on claim breadth and evidence of commercial relevance.

Estate element	Relative assessment
Amphetamine sulfate composition	Weak against ordinary generic competition because the active ingredient is established
ODT dosage form	Moderate, depending on claim scope and prior art
Excipient combination	Moderate if claims are specific and technically supported
Taste masking	Moderate to strong if claims cover measurable performance or proprietary technology
Manufacturing process	Moderate if the process is difficult to reproduce and claim scope is enforceable
Packaging and moisture protection	Narrow but commercially useful
Method of use	Potentially useful, but vulnerable to skinny-label and indication-specific strategies

A strong formulation patent typically has claims that are difficult to design around without losing the commercial performance of the product. Claims limited to routine excipients in predictable roles may face greater prior-art exposure.

What commercial opportunities does the EVEKEO ODT excipient platform create?

Pediatric adherence products

The clearest opportunity is pediatric ADHD treatment for patients who have difficulty swallowing tablets. A rapid-dispersing tablet can support:

• School-day dosing
• Caregiver-administered dosing
• Reduced dependence on water
• Easier administration during travel
• Use in children with swallowing aversion

The product is not a long-acting stimulant. Its commercial positioning therefore differs from extended-release amphetamine products and lisdexamfetamine. The ODT format is a convenience and adherence differentiator rather than a duration-of-action differentiator.

Reformulation and line-extension opportunities

The excipient platform could support additional products, subject to regulatory and patent constraints:

• New flavors with improved pediatric acceptance
• Lower-sweetener formulations
• Alcohol-free taste-masking systems
• Moisture-resistant unit-dose packaging
• ODT tablets with alternate strengths
• Combination packaging with behavioral-treatment materials
• Companion products for patients transitioning from liquid or chewable stimulants

A new strength may require additional clinical, bioequivalence, stability, and content-uniformity work. It also creates inventory and controlled-substance forecasting requirements.

Excipient technology licensing

Potential licensing targets include:

• Co-processed mannitol-cellulose excipients
• High-performance crospovidone grades
• Taste-masking systems for bitter basic drugs
• Direct-compression platforms
• Low-moisture ODT packaging
• Child-resistant, unit-dose blister systems
• Continuous manufacturing and automated weight-control systems

The strongest licensing proposition would connect an excipient to a measurable commercial benefit, such as faster disintegration, lower friability, better humidity stability, or reduced flavor load.

How do EVEKEO ODT and competing stimulant formulations compare?

Product type	Primary advantage	Excipient or formulation opportunity
EVEKEO ODT	Rapid oral disintegration without water	Taste, mouthfeel, humidity protection
Conventional amphetamine tablet	Low manufacturing complexity	Lower cost, but weaker swallowing convenience
Extended-release amphetamine capsule	Longer duration	Multiparticulate release control
Lisdexamfetamine capsule or chewable	Prodrug-based exposure profile	Taste masking and chewable texture
Methylphenidate ODT products	ODT convenience in a different stimulant class	Class substitution and adherence competition
Liquid stimulant	Flexible dosing	Palatability, preservative, and dosing-device control

EVEKEO ODT competes primarily on administration convenience within the amphetamine category. It does not replace the pharmacokinetic advantages of extended-release products.

What manufacturing and IP barriers affect EVEKEO ODT?

Manufacturing barriers include blend uniformity at low drug loading, tablet friability, punch adhesion, lubricant sensitivity, humidity exposure, and unit-dose packaging.

Amphetamine sulfate also creates controlled-substance compliance obligations. Manufacturers must manage:

• DEA registration and security
• Material accountability
• Production quotas
• Theft and diversion controls
• Inventory reconciliation
• Restricted distribution records
• Destruction and waste procedures

The manufacturing process must balance rapid disintegration against mechanical strength. Excessive compression improves handling but can slow disintegration. Excessive magnesium stearate or prolonged lubrication can create a hydrophobic tablet surface and impair wetting. Higher crospovidone levels may improve breakup but can increase friability or alter mouthfeel.

These process relationships create potential know-how barriers even when the public formulation is known.

What geographic coverage and licensing issues matter?

U.S. commercial protection depends on FDA approval, Orange Book patents, controlled-substance authorization, and U.S. manufacturing or supply arrangements. Foreign markets require separate review of:

• National patent families
• Pediatric stimulant controls
• Marketing authorization requirements
• Local excipient rules
• Flavor and sweetener restrictions
• Controlled-drug import and distribution rules
• Packaging and serialization requirements

A U.S. formulation patent may have no enforceable counterpart in a target foreign market. Conversely, a foreign patent family may cover manufacturing or packaging technology not relevant to U.S. commercialization.

Licensing transactions should define ownership of formulation improvements, manufacturing know-how, stability data, reference standards, and regulatory filings. They should also allocate controlled-substance compliance responsibilities and shortage-related supply obligations.

What is the FDA regulatory status of EVEKEO ODT?

EVEKEO ODT is an FDA-approved prescription product containing amphetamine sulfate and is classified as a Schedule II controlled substance. The label indicates use for ADHD in patients aged six years and older. The product is administered orally without water after placement on the tongue (FDA, 2023).

A generic ODT applicant would generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A 505(b)(2) pathway may be relevant to a materially different formulation, strength, delivery system, or clinical use, but it would carry a different evidentiary and exclusivity analysis.

The FDA Inactive Ingredient Database can support excipient selection by identifying prior use in approved products. It does not, by itself, establish that a proposed excipient level, combination, or pediatric exposure is acceptable (FDA, 2024b).

What revenue exposure and launch scenarios should investors monitor?

Publicly available FDA labeling does not establish EVEKEO ODT product revenue. Commercial exposure should be modeled through prescription volume, net price, payer coverage, channel mix, and generic-entry timing.

Three launch scenarios are most relevant:

Scenario	Market effect
No approved generic	Continued premium for ODT convenience, subject to stimulant competition
Single generic entrant	Price erosion and pharmacy substitution pressure
Multiple generic entrants	Rapid price compression, with differentiation limited to supply, packaging, and reliability
Reformulated branded line extension	Potential preservation of branded value if the new product has distinct duration, flavor, or administration advantages

The most defensible branded strategy is to protect the patient-experience layer: taste, disintegration, packaging, dose flexibility, and reliable supply. Active-ingredient exclusivity alone is unlikely to sustain a durable premium.

Key Takeaways

• EVEKEO ODT uses a conventional but commercially effective ODT excipient architecture built around mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and flavor.
• The principal formulation value lies in rapid disintegration, pediatric acceptability, and administration without water.
• Generic risk is substantial because amphetamine sulfate is an established active ingredient.
• The most important technical barriers are sensory matching, disintegration control, humidity stability, content uniformity, and tablet robustness.
• Orange Book patents and exclusivity records determine the operative U.S. launch timeline.
• Commercial expansion opportunities include new flavors, additional strengths, improved packaging, pediatric adherence positioning, and excipient or manufacturing licenses.
• Schedule II controls create material manufacturing, distribution, quota, security, and supply-chain barriers.
• A durable branded premium depends on patient experience and product reliability rather than active-ingredient novelty.

FAQs

Can a generic use different excipients from EVEKEO ODT?

Yes. An ANDA applicant may use different inactive ingredients if the formulation satisfies FDA requirements for safety, pharmaceutical equivalence, bioequivalence, stability, and product quality.

Is EVEKEO ODT an extended-release formulation?

No. EVEKEO ODT is an orally disintegrating immediate-release amphetamine sulfate tablet. The ODT format changes administration, not the fundamental duration-of-action profile.

Which excipient is most important for rapid EVEKEO ODT disintegration?

Crospovidone is the primary superdisintegrant, while mannitol supports rapid dissolution and acceptable mouthfeel. Performance depends on the interaction among crospovidone grade, compression force, tablet porosity, and lubrication.

Can taste masking create a separate patent opportunity?

Yes. Patentable subject matter may include specific sweetener-flavor systems, coating or particle technologies, excipient ratios, sensory-performance thresholds, and manufacturing processes. Patent strength depends on claim scope and prior art.

What is the main commercial weakness of an EVEKEO ODT line extension?

The main weakness is competition from established generic amphetamine products and longer-acting stimulant formulations. An ODT line extension must show a clear adherence, administration, flavor, dosing, or supply advantage to preserve pricing power.

References

1. U.S. Food and Drug Administration. (2023). EVEKEO ODT (amphetamine sulfate) orally disintegrating tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

3. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2024c). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.